Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Bausch + Lomb Corp (BLCO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BLCO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -38.12% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.97B USD | Price to earnings Ratio - | 1Y Target Price 18.86 |
Price to earnings Ratio - | 1Y Target Price 18.86 | ||
Volume (30-day avg) 708638 | Beta 0.48 | 52 Weeks Range 13.16 - 21.69 | Updated Date 04/2/2025 |
52 Weeks Range 13.16 - 21.69 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.9 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -6.62% | Operating Margin (TTM) 6.72% |
Management Effectiveness
Return on Assets (TTM) 0.96% | Return on Equity (TTM) -4.53% |
Valuation
Trailing PE - | Forward PE 14.99 | Enterprise Value 9406534385 | Price to Sales(TTM) 1.04 |
Enterprise Value 9406534385 | Price to Sales(TTM) 1.04 | ||
Enterprise Value to Revenue 1.97 | Enterprise Value to EBITDA 15.7 | Shares Outstanding 352471008 | Shares Floating 41284904 |
Shares Outstanding 352471008 | Shares Floating 41284904 | ||
Percent Insiders 88.41 | Percent Institutions 10.27 |
Analyst Ratings
Rating 3.5 | Target Price 20.86 | Buy 3 | Strong Buy 3 |
Buy 3 | Strong Buy 3 | ||
Hold 9 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Bausch + Lomb Corp
Company Overview
History and Background
Bausch & Lomb was founded in 1853 in Rochester, New York, by John Jacob Bausch and Henry Lomb. Initially focused on optical goods, it evolved into a global eye health company with a broad portfolio of products. It was acquired by Valeant Pharmaceuticals (now Bausch Health) in 2013 and subsequently spun off as an independent publicly traded company in May 2022.
Core Business Areas
- Vision Care: Contact lenses and lens care products, including daily disposables, reusable lenses, and solutions. Competitors include Alcon, CooperVision, and Johnson & Johnson Vision.
- Ophthalmology Pharmaceuticals: Pharmaceutical products for various eye conditions, such as glaucoma, dry eye, and ocular allergies. Competitors include Novartis, AbbVie (Allergan), and Regeneron.
- Surgical: Surgical devices and instruments for cataract and refractive surgery. Competitors include Johnson & Johnson Surgical Vision and Alcon.
Leadership and Structure
Brent Saunders is the Chairman and Joseph C. Papa was the CEO until June 2022. Thomas Appio is the current CEO. The company is structured into global business units aligned with its core business areas. The parent company is Bausch Health Companies Inc.(BHC)
Top Products and Market Share
Key Offerings
- ULTRA Contact Lenses: Monthly disposable contact lenses for astigmatism and presbyopia. Market share is estimated to be approximately 8-10% of the global reusable contact lens market. Competitors include Alcon's Air Optix, CooperVision's Biofinity, and Johnson & Johnson's Acuvue Vita.
- Biotrue ONEday: Daily disposable contact lenses. While specific market share data is difficult to find, the daily disposable lens market is rapidly growing. Competitors include Alcon's Dailies Total1, CooperVision's MyDay, and Johnson & Johnson's 1-Day Acuvue Moist.
- Lumify: Over-the-counter eye drops to relieve redness. It has gained significant market share in the OTC redness reliever category. Competitors include Visine (Johnson & Johnson) and Clear Eyes (Prestige Consumer Healthcare).
Market Dynamics
Industry Overview
The eye health market is driven by an aging population, increased prevalence of vision problems, and advancements in technology. Growth is expected in contact lenses, ophthalmic pharmaceuticals, and surgical devices.
Positioning
Bausch + Lomb holds a strong position in vision care and ophthalmic pharmaceuticals. It benefits from a well-established brand and a broad product portfolio. Key competitive advantages include its global presence and R&D capabilities.
Total Addressable Market (TAM)
The global eye care market is estimated to be worth over $170 billion. Bausch + Lomb is positioned to capture a significant share of this TAM through its diversified product offerings and global reach.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Global distribution network
- Diversified product portfolio
- Established presence in key markets
- Experienced management team
Weaknesses
- Dependence on key products
- Potential for generic competition
- Exposure to regulatory risks
- Debt obligations related to the parent company
Opportunities
- Expansion into emerging markets
- Development of innovative products
- Strategic acquisitions
- Growth in the contact lens market
- Growing market of over the counter eye care products
Threats
- Intense competition
- Economic downturns
- Changes in healthcare regulations
- Technological advancements by competitors
- Pricing pressures
Competitors and Market Share
Key Competitors
- ALC
- JNJ
- COO
Competitive Landscape
Bausch + Lomb competes with larger, more diversified healthcare companies. Bausch + Lomb's advantage lies in its focused eye health expertise and established brand. Its disadvantage is smaller size compared to some competitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth figures are combined with Bausch Health's figures prior to the 2022 spinoff
Future Projections: Analysts project moderate revenue growth for Bausch + Lomb Corp., driven by demand for contact lenses, pharmaceuticals, and surgical products. Improved profitability is expected as the company reduces debt and invests in R&D.
Recent Initiatives: Focus on strategic acquisitions to expand product portfolio, R&D investments in new technologies, and geographic expansion into emerging markets.
Summary
Bausch + Lomb is a well-established eye health company with a strong brand and diversified product portfolio. Its recent spin-off from Bausch Health presents both opportunities and challenges. The company is positioned for growth, but faces intense competition and must execute its strategic initiatives effectively. Further analysis of the company's strategy is important in evaluating its potential.
Similar Companies
ALC
Alcon AG
ALC
Alcon AG
BHC
Bausch Health Companies Inc
BHC
Bausch Health Companies Inc
COO
The Cooper Companies, Inc. Common Stock
COO
The Cooper Companies, Inc. Common Stock
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Estimates
- Bausch + Lomb Investor Relations
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share estimates are approximate and based on available data. Investment decisions should be based on individual research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bausch + Lomb Corp
Exchange NYSE | Headquaters Vaughan, ON, Canada | ||
IPO Launch date 2022-05-06 | CEO & Chairman Mr. Brenton L. Saunders J.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 13500 | Website https://www.bausch.com |
Full time employees 13500 | Website https://www.bausch.com | ||
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.